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Context: Familial pituitary adenomas occur rarely in the absence of
multiple endocrineneoplasia type1 (MEN1)andCarney complex (CNC).
Objective: Our objective was to characterize the clinical and gene-
alogical features of non-MEN1/CNC familial isolated pituitary ade-
nomas (FIPA).
Design and Setting:We conducted a retrospective study of clinical
and genealogical characteristics of FIPA cases and performed a com-
parison with a sporadic population at 22 university hospitals in Bel-
gium, Italy, France, and The Netherlands.
Results: Sixty-four FIPA families including 138 affected individuals
were identified [55 prolactinomas, 47 somatotropinomas, 28 nonse-
creting adenomas (NS), and eight ACTH-secreting tumors]. Cases
were MEN1/PRKAR1A-mutation negative. First-degree relation-
ships predominated (75.6%) among affected individuals. A single tu-
mor phenotype occurred in 30 families (homogeneous), and hetero-
geneous phenotypes occurred in 34 families. FIPA cases were younger
at diagnosis than sporadic cases (P  0.015); tumors were diagnosed
earlier in the first vs. the second generation of multigenerational
families. Macroadenomas were more frequent in heterogeneous vs.
homogeneous FIPA families (P  0.036). Prolactinomas from heter-
ogeneous families were larger and had more frequent suprasellar
extension (P  0.004) than sporadic cases. Somatotropinomas oc-
curred as isolated familial somatotropinoma cases and within heter-
ogeneous FIPA families; isolated familial somatotropinoma cases rep-
resented 18% of FIPA cases and were younger at diagnosis than
patients with sporadic somatotropinomas. Familial NS cases were
younger at diagnosis (P  0.03) and had more frequently invasive
tumors (P  0.024) than sporadic cases.
Conclusions: Homogeneous and heterogeneous expression of pro-
lactinomas, somatotropinomas, NS, and Cushing’s disease can occur
within families in the absence of MEN1/CNC. FIPA and sporadic
cases have differing clinical characteristics. FIPA may represent a
novel endocrine neoplasia classification that requires further genetic
characterization. (J Clin Endocrinol Metab 91: 3316–3323, 2006)
First Published Online June 20, 2006
Abbreviations: CNC, Carney complex; CT, computed tomography;
FIPA, familial isolated pituitary adenoma; IFS, isolated familial soma-
totropinoma; MEN1, multiple endocrine neoplasia type 1; MRI, mag-
netic resonance imaging; NS, clinically nonsecreting.
* This study was conducted with the collaboration of the Groupe
d’Etude des Tumeurs Endocrines, France.
JCEM is published monthly by The Endocrine Society (http://www.
endo-society.org), the foremost professional society serving the en-
docrine community.
PITUITARYADENOMASCANoccur in a familial settingin multiple endocrine neoplasia type 1 (MEN1) and
Carney complex (CNC) (1). MEN1 is caused by an inacti-
vating mutation in the MEN1 gene on chromosome 11q13,
which encodes the nuclear protein menin (2). The clinical
presentation of MEN1 has been extensively characterized,
andpituitary adenomas occur in about 40%of patients (3).All
tumor phenotypes can occur, but prolactinomas predom-
inate (3). Although more than 350 MEN1 gene mutations
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have been described, at least 10% of patients with clinical
features of MEN1 do not have MEN1 mutations (1). This
suggests that other causes, such as mutations in the MEN1
promoter region or in other regulatory genes, may be in-
volved in the pathophysiology of MEN1. CNC is a rare
condition that is linked in more than 50% of cases to an
inactivating mutation in the gene encoding protein kinase A
type 1A regulatory subunit (PRKAR1A) at 17q24; a second,
as yet uncharacterized, locus at 2p16 has also been implicated
(1, 4, 5). A key pathological abnormality in CNC pituitary
disease is multifocal somatomammotropic cell hyperplasia
(6). Hence, about 75% of patients with CNC exhibit subclin-
ical increases in GH, IGF-I, and prolactin levels or abnormal
responses to dynamic pituitary function tests, whereas clin-
ical acromegaly occurs in less than 10% of patients (7, 8).
Isolated familial somatotropinoma (IFS) has been reported
and is defined as the occurrence of at least two cases of
acromegaly/gigantism in a single family in the absence of
CNC or MEN1 (9); 108 affected members in 46 families have
been described to date (10). To date, studies indicate that
MEN1 and other candidate genes are unlikely to be directly
implicated in the molecular pathogenesis of IFS (11–13). A
disease locus for IFS appears to exist within a region of
approximately 2.1Mbon chromosome 11q13.3 (10, 14). Apart
from IFS, a handful of reports of other isolated pituitary
adenomas occurring in families have appeared in the liter-
ature (15–17). The scarcity of data regarding the character-
istics of these families has limited our understanding of the
clinical features and patterns of presentation of familial pi-
tuitary adenomas in patients without MEN1/CNC. To ad-
dress these issues, we undertook an international, multi-
center, retrospective study to identify non-MEN1/CNC
families with familial isolated pituitary adenomas (FIPA).
The aims of our study were to analyze the characteristics of
FIPA and to describe their phenotypic presentation com-




This retrospective study from 1970–2004 was undertaken to identify
FIPA; this was defined as families with two ormore confirmedmembers
presenting with anterior pituitary tumors and no evidence of MEN1/
CNC. In identified FIPA families, additional questioning was under-
taken to search for other affected relatives. The study was performed at
22 centers in Belgium, France, Italy, and The Netherlands, and existing
case records and databases were scrutinized for previously diagnosed
familial pituitary tumor cases. Data from 15 patients have been reported
previously (11, 13, 18–22). Informed consent for collection of personal
and clinical data was obtained from all patients; data were anonymized
before entry into a central database at the University of Lie`ge, Belgium.
Relevant demographic, genealogical, clinical, and radiological datawere
extracted from case records at individual study centers. Although the
study period was from 1970–2004, families with patients who had been
diagnosed with a pituitary tumor before 1970 were included.
Using available hormonal and clinical data, pituitary adenomas were
classified as prolactinomas, GH-secreting, clinically nonsecreting (NS),
ACTH-secreting, and TSH-secreting tumors, respectively. Gonadotropi-
nomas with a high plasma FSH were included in the NS group. MEN1
was ruled out clinically by family history and the demonstration of a
normal serum calcium and PTH in all cases, whereas in a subset of
individuals. normal levels of gastrin, vasoactive intestinal polypeptide,
and pancreatic polypeptide were also demonstrable. Patients with ac-
romegaly underwent echocardiographic studies to exclude the presence
of a cardiac myxoma related to CNC.
Neuroradiological studies consisted of a contrast-enhanced comput-
erized tomography (CT) scan of the pituitary before 1986 and magnetic
resonance imaging (MRI), predominantly with gadolinium enhance-
ment, thereafter. Based on the maximal diameter, tumors were defined
as microadenomas (10 mm), macroadenomas (10 mm), and giant
adenomas (40 mm). Invasion of the cavernous or sphenoidal sinuses
was assessed based on CT/MRI results and/or intraoperative findings.
Sporadic pituitary tumors
We compared the demographic and tumor characteristics of FIPA
cases with those of the corresponding sporadic non-MEN1, non-CNC
phenotype. This series of patientswith sporadic pituitary adenomaswas
obtained from registries of patients treated from 1970–2004 in Belgium
(Lie`ge) and Italy (L’Aquila, Rome), which comprised a total of 2600
patients. Each patient from the familial group was paired with two
patients with the same tumor phenotype extracted randomly from the
sporadic registries (Statview 5.1 software; SAS Institute, Cary, NC). A
postextraction analysis was undertaken to ensure that the familial and
sporadic groups werematchedwith respect to year at diagnosis for each
tumor phenotype; this was done to exclude bias introduced by im-
provements in diagnostic methods over the study period.
Immunohistochemistry
Among the group of patients that underwent surgery (n 83), tumor
tissue from 74 individuals was studied by immunohistochemistry for
LH, FSH, TSH, GH, prolactin, ACTH, and -subunit. GH-secreting ad-
enomas were subclassified as pure GH-secreting, mixed GH/prolactin,
or glycoprotein/GH adenomas, whereas NS adenomas were subclas-
sified as null cell, gonadotroph-secreting, or silent adenomas. Silent
adenomas were defined as tumors that were immunopositive for pitu-
itary hormones in the absence of preoperative biochemical or clinical
evidence of hormonal hypersecretion.
Genetic analysis
Blood samples were collected in all available patients, and DNA was
extracted from leukocytes. Germline mutations of theMEN1 gene were
excluded by direct sequencing of exons 1–10 in at least one affected
member of each family. In addition, sequencing of the PRKAR1A gene
was performed in one affected member of families with IFS. Informed
consent for genetic studies was obtained in all cases.
Statistical analysis
Unless otherwise specified, results are expressed in mean sd. Data
were analyzed using Statview 5.1 software (SAS Institute). As noted
above, to verify that the groups were correctly matched at time of
diagnosis, a postextraction comparison of centile distributions of year at
diagnosis in the familial and sporadic adenoma patient groups was
performed. For patients with recurrent disease, only the characteristics
at first presentation were retained for the study. Because different pat-
terns of pituitary tumor phenotypes could present within the same
kindred, families were divided into homogeneous (families presenting
with a single tumor phenotype) and heterogeneous (at least two phe-
notypes per family) groups for subsequent analyses.
Intergroup analyses were performed to compare FIPA with sporadic
adenomas and to distinguish between homogeneous and heterogeneous
subgroups, whereas multiple comparisons were used for the compar-
ison of homogeneous or heterogeneous tumorswith their sporadic coun-
terparts and for comparisons between tumor phenotypes (prolactinoma,
somatotropinoma, NS adenoma, and Cushing’s disease), respectively.
The distributions of nominal data were compared using the 2 test for
single or multiple comparisons, whereas continuous variables were
compared by the Mann-Whitney test for univariate analyses and by
ANOVA followed by the Bonferroni/Dunn post hoc test for multivariate
analyses. The analysis of parental transmission data was performed
using 2 to compare percentages of maternal/paternal transmission
with the 50% theoretical value that would occur by chance; a 2 test for
multiple comparisons was used to analyze differences among tumor
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phenotype subgroups. The level of statistical significance was P  0.05
for the two-group analyses, whereas the -level was adjusted to com-
pensate for multiple groups where necessary (e.g.   0.0167 for three
groups).
Results
Demographics and disease characteristics
A total of 64 families with isolated pituitary tumors were
identified, which included 138 affected individuals (52
males, 86 females). Within the reference study centers, FIPA
cases represented 1.9–3.2% of the total patient population
with pituitary adenomas. The mean follow-up period for
FIPA cases was 9.6  8.0 yr (median, 7 yr; range, 1–44 yr).
The sporadic group consisted of 288 patients (109 male, 179
female) with sporadic, nonfamilial, non-MEN1/CNC pitu-
itary adenomas (Table 1). There was no difference between
the FIPA and sporadic groups in terms of gender distribu-
tion, and themean year at diagnosis in both groupswas 1993.
Prolactinomas and somatotropinomas were the most prev-
alent phenotypes among the familial group, accounting for
nearly 75% of the entire series.
Fifty-five families had two affected members, eight fam-
ilies had three affected members, and one family had four
affected members. First-degree relationships (parents, off-
spring, or siblings) predominated (103 of 138, 74.6%). The
mean ( sd) total family size in the study was 15.4  9.4
individuals, and the average degree of relatedness among the
FIPA population was 0.62. When families were subdivided
according to tumor phenotype, 30 families with 62 patients
had homogeneous tumor expression; they consisted of 28
patients with prolactinoma in 14 families, 26 with soma-
totropinomas in 12 families, four with NS tumors in two
families, and four patients with Cushing’s disease in two
families. In the 34 families (76 affected individuals) exhibit-
ing heterogeneous tumor expression, up to three different
tumor phenotypeswere noted; every heterogeneous kindred
had at least one prolactinoma or somatotropinoma.
Age at diagnosis
The mean age at diagnosis was significantly lower in the
familial group as compared with the sporadic group (38.4
16.3 vs. 41.9 15.1 yr, respectively;P 0.015). This difference
was predominantly because of the younger age of patients
with IFS and familial NS adenomas compared with their
sporadic counterparts (Table 1). Furthermore, the mean age
at diagnosis in the homogeneous families was significantly
lower than in the heterogeneous families (P  0.023). In
families distributed over two generations, tumors were di-
agnosed significantly earlier in the second generation com-
pared with the first (Table 2; mean age at diagnosis, 29.0 
10.2 vs. 50.5  14.2 yr, respectively; P  0.0001). This gen-
erational effect was preserved after correction for homoge-
neous or heterogeneous in a multivariate analysis (P 
0.0001). Similarly, the second generation was diagnosed sig-
nificantly earlier than the first generation in patients with
prolactinomas, somatotropinomas, and NS adenomas occur-
ring as part of FIPA families (P  0.02). However, a gener-
ation effect independent of familial tumor status was seen
only for prolactinomas (P  0.0001).
Tumor characteristics
There was no difference between FIPA and sporadic
groups overall in terms of the frequency of micro- and mac-
roadenomas, suprasellar extension, and invasiveness, al-
though there was a trend toward a higher rate of cavernous
sinus invasion in the FIPAgroup comparedwith the sporadic
group (P  0.058; Table 1). Macroadenomas were more fre-
quent in heterogeneous than in homogeneous FIPA cases
(71.5 vs. 52.5%; P  0.036), perhaps related to the predom-
inance of NS adenomas in the heterogeneous FIPA group
and the low frequency of macroadenomas in the homoge-
neous prolactinoma group.
Individual tumor subtype characteristics
The clinical characteristics of FIPA subgroups and com-
parison with their relative sporadic counterparts are sum-
marized in Table 1.
Familial prolactinomas
Prolactinomas were the most commonly observed tumor
overall (39.9%), with 55 affected members in 40 FIPA fam-
ilies. The mean age at diagnosis was 32.6  12.5 yr (range,
15–61 yr) with a female predominance (41 females and 14
males); the age and sexdistributions of prolactinomasdid not
differ from those of sporadic prolactinomas. Prolactinomas
were equally distributed betweenhomogeneous families and
heterogeneous families. Prolactinomas in homogeneous
FIPA families were indistinguishable from sporadic prolacti-
nomas, with 71.4% (20 of 28 patients) being females with
microprolactinomas. All males (four of four) but only four of
24 females (16.7%) from homogeneous families had macro-
prolactinomas. In six of the 14 homogeneous prolactinoma
families, mother and daughter were affected, and 83.3% of
these had microprolactinomas.
Prolactinomas from heterogeneous FIPA families had
more aggressive characteristics than their homogenous
counterparts, with a largermaximal diameter (P 0.047) and
more frequent suprasellar extension (P  0.038). Compared
with their sporadic counterparts, heterogeneous prolactino-
mas were also significantly larger than their sporadic coun-
terparts (P  0.0137) and had a higher rate of suprasellar
extension (P  0.004). The percentage of males with pro-
lactinomas tended to be higher in heterogeneous than in
homogenous FIPA families (37 vs. 14.8%; P  0.053); a male
patient from a heterogeneous FIPA family developed a ma-
lignant prolactinoma, as described previously (22).
Familial somatotropinomas
Familial somatotropinomas occurred in 47 patients di-
vided among 31 families (34.1% of the series), were similarly
distributed between homogeneous/IFS and heterogeneous
FIPA families, and did not differ from sporadic cases in terms
of demographic characteristics. Patients with IFS were more
than 10 yr younger at diagnosis than those from either het-
erogeneous phenotype families (P  0.002) or sporadic so-
matotropinoma cases (P  0.0023); all five patients with
gigantism belonged to IFS families. IFS patients also had
more aggressive tumors, with extrasellar (P  0.023) and
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suprasellar extension (P  0.043) occurring more frequently
than heterogeneous somatotropinoma families. Giant tu-
mors (40 mm maximal diameter; n  2) occurred only in
IFS kindreds.
Familial NS adenomas
Twenty-eight NS adenomas were observed in 26 families,
including one case of a clinically active gonadotroph-secret-
ing adenoma. Most NS adenomas (85.7%) occurred in het-
erogeneous families. NS adenomas were diagnosed nearly 8
yr earlier in the FIPA group as compared with the sporadic
group (P 0.03). NS adenomas in the FIPA groupweremore
frequently invasive than sporadic cases (84.6 vs. 59.6%; P 
0.024).
Familial ACTH-secreting adenomas
Eight patients were affected by Cushing’s disease in five
FIPA families (homogeneous, four patients, including two
siblings, in two families; heterogeneous, four patients in
three families). The demographic and clinical characteristics
of the familial and sporadic Cushing’s disease groups did not
differ significantly from one another.
Immunohistochemistry
The diagnosis of prolactinoma was confirmed by immu-
nohistochemistry in all operated cases (n  26). Immuno-
histochemical analysis of 40 available GH-secreting tumors
demonstrated that 70% stained for GH only, 27.5% were
mixed GH/prolactin staining, and 2.5% were mixed glyco-
protein/GH-positive adenomas (2.5%). Among IFS families,
tumors exhibiting immunopositivity for GH alone or for
combinations of GH/prolactin and GH/glycoprotein hor-
mones were found to occur. Immunohistochemistry of NS
tumor tissue showed them to be null cell (n  11), FSH/
LH-positive (n  7), GH-positive (n  2) or -endorphin/
TSH -subunit-positive (n  1) adenomas. The two silent,
GH-positive, NS adenomas were giant tumors from second-
degree relatives in the same homogeneous NS phenotype
family; the other homogeneous NS tumor family comprised
a mother-son pair with silent gonadotroph-positive
adenomas.
Analysis of genealogical trees
Pituitary adenomas occurred in one in seven individuals
among the genealogies of the FIPA group overall, whereas
in generations containing at least one affected member, pi-
tuitary tumors occurred at a rate of one in 2.8 individuals. A
sizeable majority of patients in the FIPA group (103 of 138,
74.6%) were first-degree relatives of other affected members.
Potential parental transmission was studied in 78 genera-
tions and was identified in 66 patients from 48 families. A
total of 38 of 66 (57.6%) of cases indicated potential maternal
transmission, which did not differ significantly from the 50%
that would be expected by chance (2  1.51; P value not
significant). A significantly high level of potential maternal
transmission was seen in 69.7% of the homogeneous FIPA
group (2  5.12; P  0.05). For all prolactinomas, potential
maternal transmission occurred in 74.2% of cases (2 
7.26; P  0.01) because of frequent maternal transmission
among homogeneous prolactinoma families (81.2%; 2  6.25;
P  0.02). In IFS families, tumors occurred predominantly
among siblings (65.4%), whereas data in FIPA families with
NS tumors and Cushing’s disease were insufficient for a
robust assessment of parental transmission.
Genetic studies
Germline mutations in exons 1–10 of theMEN1 gene were
excluded in at least one affected member of each family (90
patients were tested); upstream and downstream elements
related to MEN1 were not assessed. Mutations in the
TABLE 2. Mean ages at diagnosis in the first and second generations of multigenerational families with FIPA according to tumor
phenotype and pattern of presentation
Tumor type Age at diagnosis(first generation)
Age at diagnosis
(second generation) P value
Overall
All phenotypes (n  80 in 37 families) 50.5  14.2 29.0  10.2 0.0001a
All homogeneous (n  29 in 14 families) 43.2  12.8 24.4  6.6
All heterogeneous (n  51 in 23 families) 54.4  13.4 31.8  11.0 0.0001b
Individual phenotypes
All prolactinomas (n  41 in 29 families) 44.7  8.3 26.7  9.0 0.0001a
Homogeneous (n  22 in 11 families) 44.4  9.2 23.3  4.6
Heterogeneous (n  19 in 18 families) 45.7  5.8 29.2  10.7 0.0001b
All somatotropinomas (n  20 in 16 families) 53.3  17.4 34.4  12.3 0.02a
Homogeneous (n  5 in 2 families) 27.0  18.4 26.0  12.8
Heterogeneous (n  15 in 14 families) 58.1  12.9 40.7  8.2
All NS adenomas (n  18 in 17 families) 56.0  15.0 32.1  10.8 0.006a
Homogeneous (n  2 in 1 family) 63.0 32.0
Heterogeneous (n  16 in 16 families) 55.3  15.6 32.2  11.8
The ages at diagnosis are expressed as mean  SD.
a One-way comparison between the first and second generations.
b Significant difference in age after a two-way analysis after exclusion of a significant interaction between generation and familial subtype
status.
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PRKRA1A gene were found to be negative in at least one
member from 11 of 12 families with a homogeneous acro-
megaly phenotype. One homogeneous, two-member IFS
family was screened for MEN1 but was not available for
PRKRA1A gene screening. However, the subjects had no
cardiac, cutaneous, or endocrine abnormalities that were
suggestive of CNC.
Discussion
Pituitary tumors that occur in a familial setting due to
MEN1, CNC, or IFS account for a minority of pituitary tu-
mors overall. Scheithauer et al. (23) estimated that 2.7% of
pituitary adenomaswere due toMEN1, whereas acromegaly
due to CNC or IFS together account for no more than a few
hundred cases worldwide (1, 8, 9). The current study indi-
cates that FIPA may account for a similar proportion (2.5%)
of pituitary adenomas to MEN1, suggesting that hereditary
tumor syndromesmay play a role in the clinical presentation
of about 5% of pituitary tumors (24).
Familial prolactinoma unrelated to MEN1 was first de-
scribed by Berezin and Karasik (16). In this study, we have
characterized familial prolactinoma further in a large num-
ber of patients (n  55). In line with the epidemiology of
sporadic pituitary tumors (25), prolactinoma was the most
frequently encountered tumor in FIPA families (39.9% of
cases). Prolactinomas in the heterogeneous FIPA groupwere
larger and had more frequent suprasellar extension than the
homogeneous group. This may have been because of the
presence of relatively more males in the heterogeneous pro-
lactinoma group, because the clinical course of prolactinoma
is thought to be generally more aggressive in males (26).
Somatotropinomas accounted for about one third of FIPA
cases. Although IFS has been characterized previously, in
this study we noted that acromegaly cases could also occur
in conjunction with prolactinomas, NS adenomas, or Cush-
ing’s disease in the same family. Among the IFS group (18%
of FIPA cases), six families with 14 affected individuals (two
three-member families and four two-member families) have
not been reported previously, increasing the reported num-
ber of IFS cases to 122 overall. Patients with IFS were diag-
nosed more than a decade before those with sporadic so-
matotropinomas or somatotropinomas occurring in
heterogeneous FIPA families, whereas all five cases of gi-
gantism occurred in families with IFS. These results are in
keeping with the previously reported early median age at
diagnosis (26 yr) in patients with IFS (27). Similarly, supra-
sellar/extrasellar extension was more frequent in IFS than in
the heterogeneous FIPA groups, mirroring previous reports
of acromegaly being more aggressive in younger subjects
(28). In contrast to previous reports of male predominance in
IFS, however, equal sex distribution of somatotropinomas
was seen in our series. NS adenomas occurred predomi-
nantly as part of heterogeneous FIPA families and were
diagnosed earlier and were more frequently invasive than
sporadic NS adenomas. No particular characteristics could
be observed in the eight patients with familial Cushing’s
disease.
AllMEN1 gene mutation studies performed in the patient
population were negative, which strongly suggests that
FIPA, including patients characterized as IFS, represents an
entity/entities unrelated to MEN1. In support of this, serum
calcium and PTH were normal in all cases, and no abnor-
malities developed throughout follow-up; normal gastrin,
vasoactive intestinal polypeptide, and pancreatic polypep-
tide levelswere observed in the subgroup tested. A pituitary-
restricted form of CNC was largely ruled out by normal
PRKAR1A sequences in IFS families, whereas CNC-related
multifocal somatomammotropic hyperplasia (6) was not re-
ported in pituitary tumor samples. Echocardiography was
also negative for CNC-related atrial myxomas in patients
with somatotropinomas. Although these data do not entirely
exclude the role of a potential disease locus on chromosome
2p16, CNC in somatotropinoma patients in this series is
unlikely.
How do the characteristics of FIPA compare with the re-
spective characteristics of pituitary tumors that occur in the
setting of MEN1? Verge`s et al. (3) described the character-
istics of 136 MEN1 patients with pituitary adenomas from a
group of 324 patients with demonstrated MEN1 mutations.
Approximately 75% of pituitary adenomas were diagnosed
before the age of 51 yr in FIPA, which is older than the
corresponding age (46 yr) in MEN1 (3). Macroadenomas
predominated in MEN1-related pituitary adenoma cases
(85%), and invasion occurred in one third of tumors. These
results are not mirrored by FIPA, because tumor size and
invasion did not differ significantly between the overall FIPA
group and the sporadic cases. Both FIPA andMEN1pituitary
adenomas have a female preponderance, with prolactinomas
being the most frequent phenotype encountered. In MEN1,
the percentage of prolactinomas (62.5%) is markedly higher
than in FIPA (39.9%) (3). Somatotropinomas, on the other
hand, accounted for 34.1% of tumors in FIPA, comparedwith
only 8.8% of tumors in MEN1 (3).
The epidemiology of sporadic pituitary adenomas and
aspects of the genealogical data in this series indicate that the
occurrence of uncommon pituitary tumors within multiple
members of individual families, as seen in FIPA (Fig. 1), is
more likely to occur because of inherited factors rather than
by chance. This has been noted previouslywith respect to IFS
(27). The prevalence of pituitary tumors within FIPA family
trees is higher (one in seven individuals) than the historical
prevalence of clinically active pituitary adenomas in the gen-
eral population (190–280 per million) (29, 30). Although a
recent meta-analysis of MRI and autopsy data suggested a
high frequency of pituitary adenomas, many of these tumors
were detected incidentally (31). Analysis of genealogical
trees suggests autosomal dominant inheritancewith variable
penetrance as a general model, as has been hypothesized
previously for IFS (27). Additional epidemiological studies
will be required to assess the frequency of clinically active
pituitary tumors in the modern diagnostic era; such data
would help to determine accurately disease risk ratios and
familiality in FIPA. This point is relevant to the FIPA pop-
ulation overall, with 74.6% of cases occurring in first-degree
relatives, and chance is even less likely in families with more
than two affected members. The period of follow-up (34 yr)
may not have been sufficient, however, to identify patterns
of disease across many generations, which could bias re-
porting toward first-degree relatives. Maternal transmission
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was significantly in excess of 50% in homogeneous prolacti-
noma families. The finding that patients from the second
generation were diagnosed significantly earlier than the first
generation in multigenerational FIPA families is intriguing
and is suggestive of genetic anticipation, although a signif-
icant generational effect independent of familial tumor status
could be documented reliably only for prolactinomas. Al-
ternatively, other factors unrelated to the disease process
itself may be involved, including increased awareness of
symptoms within the family or improvements in diagnostic
methods.
In conclusion, this multicenter, retrospective study indi-
cates that FIPA may represent a new clinical entity/entities
that includes IFS, and is unlikely to be related to MEN1 or
CNC. Heterogeneous or homogeneous tumor phenotypes
can occurwithin FIPA,whichmay indicate sharedmolecular
pathophysiological mechanisms.
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